Visit https://www.peervoice.com/HES860 to view the entire programme with slides. After completing “Targeting Pro-Tumorigenic Inflammation in NSCLC: Evolving Strategies to Improve Patient Outcomes”, participants will be able to: Discuss the role of pro-tumour inflammation (PTI) in promoting cancer growth and metastasis; Evaluate the potential for reductions in cancer incidence, cancer morbidity, and mortality with IL-1β–targeted agents aimed at reducing PTI